Passiflora for anxiety disorder

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Miyasaka, Lincoln Sakiara ^a   Atallah, A N ^b   Soares, B G O ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

*Passiflora; Anxiety disorders *drug therapy ; Benzodiazepines therapeutic use ; Humans; Phytotherapy adverse effects; *methods ; Randomized controlled trials as topic

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; IMIPRAMINE; MEXAZOLAM; OXAZOLAM; PASSIFLORA EXTRACT; PLANT EXTRACT; RITANSERIN; TRAZODONE;

AGORAPHOBIA; ALLERGIC REACTION; ANXIETY DISORDER; DIZZINESS; DRUG EFFICACY; HAMILTON ANXIETY SCALE; HERBAL MEDICINE; HUMAN; MENTAL DISEASE; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; REVIEW; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; SYSTEMATIC REVIEW;

EID: 44949137388     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004518.pub2     Document Type: Review

References (24)

1. Akhondzadeh 2001 {published data only} Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics 2001;26:363-367.
2. Mori 1993 {published data only} Mori A, Hasegawa K, Murasaki M, Yamauchi T, et al.Clinical Evaluation of Passiflamin (passiflora extract) on neurosis - multicenter double blind study in comparison with mexazolam. Clinical Evaluation 1993;21:383-440.
3. Bourin 1997 *Bourin M, Bougerol T, Guitton B, Broutin E. A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundamental & Clinical Pharmacology 1997;11(2):127-32.
4. Almeida-Filho 1997 Almeida-Filho N, Mari JJ, Coutinho E, Franca JF, Fernades J, Andreoli SB, et al.Brazilian multicentric study of psychiatric morbidity. Methodological features and prevalence estimates. British Journal of Psychiatry 1997;171:524-9.
5. Bijl 1998 Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of the Netherlans Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry & Psychiatric Epidemiology 1998;33(12):587-95.
6. Borkovec 1987 Borkovec TD, Mathews AM, Chambers A, Ebrahimi S, Lytle R, Nelson R, et al.The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety disorder. Journal of Consulting & Clinical Psychology 1987;55(6):883-8.
7. Borkovec 1993 Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive behavioral therapy in the treatment of generalized anxiety disorder. Journal of Consulting & Clinical Psychology 1993;61(4):611-9.
8. Clarke 2000 Clarke M, Oxman AD. Cochrane Collaboration Handbook. Oxford: Update Software, 2000.
9. Fisher 2000 Fisher AA, Purcell P, Le Couteur DG. Toxicity of Passiflora incarnata. Clinical Toxicology 2000;38(1):63-6.
10. Gould 1997 Gould RA, Otto MW. Pollack MH, Yap L. Cognitive behavioural and pharmacological treatment of generalized anxiety disorders: a preliminary meta-analysis. Behaviour Therapy 1997;28(2):285-305.
11. Hamilton 1959 Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-5.
12. Hunot 2006 Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder [Psychotherapy for generalized anxiety disorder]. Cochrane Database of Systematic Reviews 2006, Issue 4.
13. Jadad 1996 Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
14. Kessler 1994 Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al.Lifetime and 12 month prevalence of DSM III R psychiatric disorders in the United States. Archives of General Psychiatry 1994;51(1):8-19.
15. Mendlowicz 2000 Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. American Journal of Psychiatry 2000;157(5):669-82.
16. Newall 1996 Newall. Herbal medicines: a guide for health care professionals. London, England: The Pharmaceutical Press of Great Britain, 1996.
17. Olin 1989 Olin B. Passion Flower monograph. The Lawrence review of natural products. Facts and comparisons. St Louis, MO: Wolters Kluwer Company, 1989.
18. Pittler 2002 Pitter MH, Ernst E. Kava extract for treating anxiety. Cochrane Database of Systematic Reviews 2002, Issue 2.
19. Priest 1988 Priest RG, Montgomery SA. Benzodiazepines and dependence: A college statement. Bulletin of the Royal College of Psychiatrists 1988;12:107-8.
20. Rickels 1993 Rickels K, Downing R, Schweizer E, et al.Antidepressants for the treatment of generalized anxiety disorder: aplacebo controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993;50:884-895.
21. Schulz 1995 Schulz KF, Chalmmers I, Haves RJ, Altman DG. Empirical evidence of bias: dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
22. Taylor 1978 Taylor CB. In: Agras WS editor(s). Relaxation training and related techniques In: Behavioral modifications: principles and clinical applications. Boston, MA: Little Brown, 1978.
23. Taylor 1988 Taylor CB, Arnow B. The nature and the treatment of anxiety disorders. New York, NY: Free Press, 1988.
24. Walley 1994 Walley EJ, Beebe DK, Clark JL. Management of common anxiety disorders. American Family Physician 1994;50(8):1745-53.